Ads
related to: faricimab svoa brand name list
Search results
Results From The WOW.Com Content Network
Faricimab, sold under the brand name Vabysmo (/ v ə ˈ b aɪ z m oʊ / və-BYEZ-mow), is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
The FDA has approved Genentech's, a unit of Roche Holdings AG (OTC: RHHBY), Vabysmo (faricimab-svoa) for wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema (DME).
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Aflibercept, sold under the brand names Eylea and Zaltrap among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. [14] [15] It was developed by Regeneron Pharmaceuticals. It is an inhibitor of vascular endothelial growth factor (VEGF).
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
The names on the list are the ISO common name for the active ingredient which is formulated into the branded product sold to end-users. [1] The University of Hertfordshire maintains a database of the chemical and biological properties of these materials, [2] including their brand names and the countries and dates where and when they have been ...
Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, COVID‑19, and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
The Oxford–AstraZeneca COVID-19 vaccine, sold under the brand names Vaxzevria [6] and Covishield, [7] is a viral vector vaccine [8] produced by the British University of Oxford, British-Swedish company AstraZeneca, and the Coalition for Epidemic Preparedness Innovations.